Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa

Abstract

BackgroundAntivenom is the treatment of choice for snakebite, which annually kills an estimated 32,000 people in sub-Saharan Africa and leaves approximately 100,000 survivors with permanent physical disabilities that exert a considerable socioeconomic burden. Over the past two decades, the high costs of the most polyspecifically-effective antivenoms have sequentially reduced demand, commercial manufacturing incentives and production volumes that have combined to create a continent-wide vacuum of effective snakebite therapy. This was quickly filled with new, less expensive antivenoms, many of which are of untested efficacy. Some of these successfully marketed antivenoms for Africa are inappropriately manufactured with venoms from non-African snakes and are dangerously ineffective. The uncertain efficacy of available antivenoms exacerbates the complexity of designing intervention measures to reduce the burden of snakebite in sub-Saharan Africa. The objective of this study was to preclinically determine the ability of antivenoms available in Kenya to neutralise the lethal effects of venoms from the most medically important snakes in East Africa.MethodsWe collected venom samples from the most medically important snakes in East Africa and determined their toxicity in a mouse model. Using a ‘gold standard’ comparison protocol, we preclinically tested the comparative venom-neutralising efficacy of four antivenoms available in Kenya with two antivenoms of clinically-proven efficacy. To explain the variant efficacies of these antivenoms we tested the IgG-venom binding characteristics of each antivenom using in vitro IgG titre, avidity and venom-protein specificity assays. We also measured the IgG concentration of each antivenom.FindingsNone of the six antivenoms are preclinically effective, at the doses tested, against all of the most medically important snakes of the region. The very limited snake polyspecific efficacy of two locally available antivenoms is of concern. In vitro assays of the abilities of ‘test’ antivenom IgGs to bind venom proteins were not substantially different from that of the ‘gold standard’ antivenoms. The least effective antivenoms had the lowest IgG content/vial.ConclusionsManufacture-stated preclinical efficacy statements guide decision making by physicians and antivenom purchasers in sub-Saharan Africa. This is because of the lack of both clinical data on the efficacy of most of the many antivenoms used to treat patients and independent preclinical assessment. Our preclinical efficacy assessment of antivenoms available in Kenya identifies important limitations for two of the most commonly-used antivenoms, and that no antivenom is preclinically effective against all the regionally important snakes. The potential implication to snakebite treatment is of serious concern in Kenya and elsewhere in sub-Saharan Africa, and underscores the dilemma physicians face, the need for clinical data on antivenom efficacy and the medical and societal value of establishing independent preclinical antivenom-effica...

Evaluation of the geographical utility of Eastern Russell’s viper (Daboia siamensis) antivenom from Thailand and an assessment of its protective effects against venom-induced nephrotoxicity

“…The exception to this is perhaps proteins observed in the 50-100 kDa molecular weight range, where lower binding between both antivenoms and the venoms was observed, with those from Myanmar and Taiwan exhibiting the lowest cross-reactivity. While immunological assays alone cannot be used to define the likely preclinical efficacy of an antivenom [26, 29], strong immunological characteristics are an essential prerequisite for venom neutralization in vivo . Thus, our findings from ELISA and immunoblotting experiments suggest that the Thai DSAV and HPAV antivenoms may neutralise D. siamensis venom from different parts of its range, and thus may be a useful clinical tool across Southeast Asia.…”

“…The chaotropic ELISA assay was performed as previously described [26]. In brief, the assay was performed as per the EPT ELISA assay detailed above, except that the antivenoms and normal horse IgG were diluted to a single concentration of 1:10,000, incubated overnight at 4 °C, washed with TBST and then a chaotrope, ammonium thiocyanate (NH 4 SCN), added to the wells in a range of concentrations (0-8 M) for 15 minutes.…”

The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms

“…Experimental design was based upon refined WHO-recommended protocols 8,11,16,53 . We first determined the median lethal dose (venom LD 50 ) of E. ocellatus and D. typus venom, as previously described 8 .…”

High throughput screening and identification of coagulopathic snake venom proteins and peptides using nanofractionation and proteomics approaches

“…However, despite these products saving thousands of lives every year, they possess a number of technical limitations that ultimately restrict their clinical utility. Antivenoms exhibit limited paraspecific efficacy (with efficacy restricted mostly to the species used for immunisation), have poor dose efficacy (only 10-20% of antivenom antibodies are typically specific to the toxin immunogens) and exhibit high incidences of adverse effects (which can be as high as in 75% of cases) (6–8). Critically, these therapies are expensive, ranging from $50-350 per vial in Africa, for example (6).…”